Oxolamine citrate

SKU:BHB21902672
Overview
Click light‑blue chips for details
Oxolamine citrate (CAS 1949-20-8) is a bioactive small molecule supplied as a solid. Reported to act on CYP2B1, CYP2B2. Relevant to Metabolic Enzyme/Protease research. Molecular formula C20H27N3O8, molecular weight 437.44 g/mol.
Purity 99.87%
CAS Number 1949-20-8
Molecular Weight 437.44 g/mol
Form Solid
Target CYP2B1, CYP2B2
Storage 4°C as supplied; in solvent -80°C
Options selector
Catalog no. Size
HY-B1042-500MG 500 mg
HY-B1042-1G 1 g
HY-B1042-5G 5 g
HY-B1042-10G 10 g
HY-B1042-1MLX10MM 1 mL x 10 mM (in DMSO)
Available Options

Select the variant that best fits your experiment. Availability and lead time may vary by option.

  • Options: Size: 500 mg, 1 g, 5 g, 10 g, 1 mL x 10 mM (in DMSO)
  • Lead time: varies by selected option.
  • Storage: 4°C, sealed storage, away from moisture. In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture).
  • Shipping: Room temperature in continental US; may vary elsewhere.
  • Upon receipt: refrigerate at 4°C as soon as possible.
Field Specification
Target CYP2B1, CYP2B2
Alternative names SKF-9976 citrate; AF-438 citrate
CAS no. 1949-20-8
Applications
  • Functional Assay (In Vitro)
Molecular weight 437.44
Molecular formula C20H27N3O8
Purity 99.87%
SMILES CCN(CC)CCC1=NC(C2=CC=CC=C2)=NO1.O=C(CC(C(O)=O)(O)CC(O)=O)O
Form Solid
Storage 4°C, sealed storage, away from moisture. In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture).
Shipping Room temperature in continental US; may vary elsewhere.
Catalog no. (Mfr.) HY-B1042
Main SKU BHB21902672
Bioactive Small Molecules

Compound Overview

Oxolamine citrate, also known as SKF-9976 citrate or AF-438 citrate, is an orally active antitussive that can inhibit CYP2B1/2. It has anti-inflammatory effects on the respiratory organs of guinea pigs, increases the AUC of Warfarin, and prolongs its terminal half-life. It can be used in respiratory disease research[1][2][3][4]. It is supplied as a white to off-white solid (C20H27N3O8, MW 437.44) at 99.87% purity.

Physical & Chemical Properties

CAS Number 1949-20-8
Molecular Formula C20H27N3O8
Molecular Weight 437.44 g/mol
Purity 99.87%
Appearance Solid
Color White to off-white
SMILES CCN(CC)CCC1=NC(C2=CC=CC=C2)=NO1.O=C(CC(C(O)=O)(O)CC(O)=O)O
Target CYP2B1, CYP2B2
Signaling Pathway Metabolic Enzyme/Protease
Solubility In Vitro: DMSO: ≥ 100 mg/mL (228.60 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O: 14.29 mg/mL (32.67 mM; Requires sonication) * "≥" means soluble, but saturation unknown.
Storage 4°C, sealed storage, away from moisture. In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture).
Shipping Room temperature in continental US; may vary elsewhere.

Literature Cited

Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.

[1]. Kirilmaz L, et al. Sustained-release dosage form of oxolamine citrate: preparation and release kinetics. J Microencapsul. Apr-Jun 1992;9(2):167-72.

[2]. GIUDICI G, et al. [On the anti-inflammatory action of oxolamine citrate]. Minerva Med. 1961 Oct 31;52:3752-5.

[3]. Zhu X, et al. Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. Biopharm Drug Dispos. 2007 Apr;28(3):125-33.

[4]. Dahlgren S, et al. The effect of oxolamine citrate on experimentally produced inflammation in the respiratory organs. Acta Pharmacol Toxicol (Copenh). 1966;24(2):286-96.

Safety

For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.

In Vitro

SolventSolubilityNotes
DMSO≥ 100 mg/mL (228.60 mM)use freshly opened DMSO (absorbed moisture lowers solubility)
H2O14.29 mg/mL (32.67 mM)requires sonication

Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); sealed storage, away from moisture; avoid repeated freeze-thaw cycles.

If water is used as the stock solvent, dilute to the working solution and sterilize it through a 0.22 μm filter before use.

In Vivo

Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.

Protocol 1

Composition10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline
Result≥ 2.5 mg/mL (5.72 mM); clear solution
How to prepareGives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL.

Protocol 2

Composition10% DMSO + 90% (20% SBE-β-CD in saline)
Result≥ 2.5 mg/mL (5.72 mM); clear solution
How to prepareGives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week).

Protocol 3

Composition10% DMSO + 90% Corn Oil
Result≥ 2.5 mg/mL (5.72 mM); clear solution
How to prepareGives a clear solution at ≥ 2.5 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL corn oil.

Direct preparation of the working solution

These formulations are prepared directly, without a DMSO stock; use them promptly after preparation.

Protocol 4

CompositionPBS
Result28 mg/mL (64.01 mM); clear solution; requires sonication

Data provided by the manufacturer.

In Vitro

In fresh rat plasma, Oxolamine (10 μg/mL; 24 h) citrate significantly lowers the plasma protein binding of Clarithromycin[3].

In Vivo

In male SD rats, Oxolamine citrate (10-50 mg/kg; p.o.; 3 times daily for 3 consecutive days) significantly raises the AUC and extends the terminal half-life of Warfarin[3]. Oxolamine citrate (initially 80 mg/kg body weight, then 53.3 mg/kg; i.p.; administered 11 times at 3, 6, 9, 24, 28 and 32, then 48, 52, 56, 72 and 76 h) produces a distinct anti-inflammatory effect on the respiratory organs of guinea pigs[4].

Animal ModelGuinea pigs + non-bacterial inflammation of the respiratory tract model induced by inhalation of acrolein aerosol[4]
Dosage80 mg/kg body weight initially, then 53.3 mg/kg
AdministrationIntraperitoneal injection, 11 times at 3, 6, 9, 24, 28, 32, 48, 52, 56, 72 and 76 h
ResultReduced relative lung weight. Significantly reduced inflammation levels. Protected the pulmonary parenchyma from emphysema. Showed anti-inflammatory effect superior to that of Phenylbutyrone.

Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.

Q.Why is there no price on some sizes?
A.Availability and lead time for those sizes are confirmed on inquiry. Send us the size you need and we will come back with price and lead time.
Q.Can this be used in humans or for diagnostics?
A.No. This product is supplied For Research Use Only. It is not for diagnostic or therapeutic procedures and not for human or veterinary use.

Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.

  • Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
  • Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
  • Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
  • QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
  • Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity

To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).

Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).

Get a Quote

Please use this form for bulk quantity requests or customized products.

Contact Information

Product Information

Try Celltrypse Free – Request Your Sample Today

Experience the power of Celltrypse™, c-LEcta's innovative enzyme solution for gentle and efficient cell dissociation. Request your free sample and discover a superior alternative for your cell culture workflows.

Try Celltrypse Free – Request Your Sample Today

Try Celltrypse Free – Request Your Sample Today

Experience the power of Celltrypse™, c-LEcta's innovative enzyme solution for gentle and efficient cell dissociation. Request your free sample and discover a superior alternative for your cell culture workflows.

Try Celltrypse Free – Request Your Sample Today